Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bispecific antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co. Inc.
Deal Size: $891.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration July 08, 2020
Details:
Under the terms of the new research and license agreement, Zymeworks will provide Merck a worldwide, royalty-bearing license to research, develop and commercialize up to three new multispecific antibodies toward Merck’s therapeutic targets.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EPI-7386,Enzalutamide
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
The study highlighted full-length AR target engagement by EPI-7386, Its In vitro cellular gene expression analyses, Toxicology studies evaluating the safety profile of EPI-7386 and its starting clinical dose.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cannabidiol
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
Details:
Jay Pharma received institutional review board approval by Rabin Medical Center in Petah Tikva, Israel for a Phase I/II clinical trial investigating Jay Pharma's proprietary cannabidiol formulation for the treatment of glioblastoma multiforme.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TH1902
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
Details:
New peptide-curcumin conjugate, TH1901, shows 100 times greater anti-cancer cell proliferation activity than unconjugated curcumin in vitro.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Doxorubicin peptide conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
Details:
Both TH1902 (docetaxel peptide conjugate) and TH1904 (doxorubicin peptide conjugate), are more effective and better tolerated in animal models than two commonly-used ovarian cancer treatments.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
